PR Newswire
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors
📈
AI Sentiment
Highly Positive
8/10
Alnylam Pharmaceuticals Inc. News
Latest updates and market news for ALNY
6 news
Feb 26 - Mar 4, 2026
Page 1
MarketBeat
Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf.
📈
AI Sentiment
Highly Positive
9/10
CNW Group
Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis
📈
AI Sentiment
Highly Positive
9/10
GlobeNewswire
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock
📈
AI Sentiment
Highly Positive
10/10
Simply Wall St.
Does Alnylam Pharmaceuticals (ALNY) Price Reflect Its RNAi Pipeline Potential?
📊
AI Sentiment
Positive
6/10
Share this news page